Featured Research

from universities, journals, and other organizations

SESAME stent trial demonstrates 100% acute success rate in patients undergoing angioplasty of degenerated saphenous vein graft lesions

Date:
November 16, 2010
Source:
Wiley - Blackwell
Summary:
A new study revealed that the novel self-expanding super-elastic all-metal endoprosthesis stent (SESAME StentTM) used in patients undergoing angioplasty of degenerated saphenous vein graft (SVG) lesions has 100% acute success, low 30 day major adverse cardiac events (MACE) rates, and 9-month patency comparable to balloon expandable stents without embolic protection.

A new study revealed that the novel self-expanding super-elastic all-metal endoprosthesis stent (SESAME StentTM) used in patients undergoing angioplasty of degenerated saphenous vein graft (SVG) lesions has 100% acute success, low 30 day major adverse cardiac events (MACE) rates, and 9-month patency comparable to balloon expandable stents without embolic protection. Results of the study are published in the November issue of Catheterization and Cardiovascular Intervention, a peer-reviewed journal from The Society for Cardiovascular Angiography and Interventions.

Percutaneous coronary intervention (PCI), or angioplasty, is a procedure to alleviate plaque buildup due to atherosclerosis. A thin catheter containing a small balloon is inserted into an artery and threaded toward the heart to the blockage. The balloon is then inflated to push back the plaque and restore blood flow to the heart, and a wire mesh tube called a stent is usually put in place to prevent re-blocking.

PCI of old, degenerated saphenous vein grafts (SVGs) is a challenging and risky procedure. Diseased SVGs are complicated, thrombotic lesions associated with a higher risk of plaque and thrombus embolization, making the placement of embolic distal protection devices during PCI difficult. Up to half of patients with SVGs receiving bare metal stents have restenosis or occlusion within 6-12 months following stent implantation. There are no self-expanding stents specifically used to treat SVG disease. Prior adjunctive therapies such as antiplatelet agents and covered stents have not been effective in improving procedural outcomes of SVG PCI.

The Advanced Bioprosthetic SurfacesTM SESAME stent offers a system that limits plaque protrusion through the stent struts and limits stent strut migration into the underlying plaque. The microporous mesh of the SESAME stent is an improvement over the polymer covers used in other stents for SVG implantation because it allows improved vascular healing and tissue regrowth over the sent (endothelialization). Biocompatibility studies indicate metals are advantageous over polymers, suggesting that a metal membrane should be a good choice for a covered-stent.

The SESAME First in Man trial is a prospective, multicenter registry of 20 nonrandomized consecutive patients with 21 stenotic SVGs treated electively at two centers between February 2005 and August 2005. Patients underwent elective intervention of symptomatic SVG lesions with 50% stenosis. PCI was performed without embolic protection devices.

"The SESAME trial is the first study to prospectively demonstrate that a self-expanding microporous membrane-covered stent can be safely used with a high success rate in treating complex SVG lesions even in the absence of embolic protection devices," comments study leader Steven R. Bailey, MD, FSCAI, from the University of Texas Health Sciences Center in San Antonio. Technical success -- successful crossing of the lesion and deployment of the device -- was achieved in 100% of lesions using the SESAME stent. A 100% procedural success rate, defined as a residual stenosis of less than 50% stenosis post stent and no MACE, was also achieved.

No procedural or in hospital complications occurred. Follow-up was present in 20 patients at 30 days, with clinical and angiographic evaluation at 9 months. No MACE events occurred at 30 days. At 9 months, 3 patients underwent repeat PCI. Dr. Bailey concluded, "Even in severely degenerate SVG lesions, interventionists can safely achieve a high primary success rate with low MACE during the initial 30 days following the procedure."


Story Source:

The above story is based on materials provided by Wiley - Blackwell. Note: Materials may be edited for content and length.


Journal Reference:

  1. Alexander Abizaid, Bonnie Weiner, Steven R Bailey, Hugo Londero. Use of a self-expanding super-elastic all-metal endoprosthesis; To treat degenerated SVG lesions: The SESAME first in man trial. Catheterization and Cardiovascular Interventions, 2010; DOI: 10.1002/ccd.22687

Cite This Page:

Wiley - Blackwell. "SESAME stent trial demonstrates 100% acute success rate in patients undergoing angioplasty of degenerated saphenous vein graft lesions." ScienceDaily. ScienceDaily, 16 November 2010. <www.sciencedaily.com/releases/2010/11/101116093823.htm>.
Wiley - Blackwell. (2010, November 16). SESAME stent trial demonstrates 100% acute success rate in patients undergoing angioplasty of degenerated saphenous vein graft lesions. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2010/11/101116093823.htm
Wiley - Blackwell. "SESAME stent trial demonstrates 100% acute success rate in patients undergoing angioplasty of degenerated saphenous vein graft lesions." ScienceDaily. www.sciencedaily.com/releases/2010/11/101116093823.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins